Human medicines European public assessment report (EPAR): Albrioza, sodium phenylbutyrate,Ursodoxicoltaurine, Date of refusal: 05/01/2024, Status: Refused

Human medicines European public assessment report (EPAR): Albrioza, sodium phenylbutyrate,Ursodoxicoltaurine, Date of refusal: 05/01/2024, Status: Refused

Orphan designation: Humanised IgG1 monoclonal antibody against TfR1 conjugated to exon 44 specific phosphorodiamidate morpholino oligonucleotide via a non-cleavable linker Treatment of Duchenne muscular dystrophy, 13/10/2023 Positive

Orphan designation: Humanised IgG1 monoclonal antibody against TfR1 conjugated to exon 44 specific phosphorodiamidate morpholino oligonucleotide via a non-cleavable linker Treatment of Duchenne muscular dystrophy, 13/10/2023 Positive

Orphan designation: 2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol Treatment of myelofibrosis, 13/10/2023 Positive

Orphan designation: 2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol Treatment of myelofibrosis, 13/10/2023 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness